European Journal of Vascular & Endovascular Surgery
Volume 36, Issue 5 , Pages 507-516 , November 2008

Plaque Biology: Interesting Science or Pharmacological Treasure Trove?

Received 5 June 2008 ,Accepted 5 June 2008.

References 

  1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809
  2. Buja LM, Willerson JT. Role of inflammation in coronary plaque disruption. Circulation. 1994;89:503–505
  3. Suckling KE. The vulnerable atherosclerotic plaque. Emerging Drugs. 1998;3:121–134
  4. Pauriah M, Struthers AD, Lang CC. Biomarkers and surrogate endpoints in cardiovascular therapeutics research: under scrutiny following results of the ENHANCE study. Cardiovasc Ther. 2008;26:85–88
  5. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95
  6. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extra cellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69:377–381
  7. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PRF, et al. Increased MMP-9 activity in unstable carotid plaques- a potential role in acute plaque disruption. Stroke. 2000;31:40–47
  8. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36–44
  9. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation. 1993;87:1179–1187
  10. MacIsaac AI, Thomas JD, Topol EJ. Toward the quiescent coronary plaque. J Am Coll Cardiol. 1993;22:1228–1241
  11. Tofler GH, Stone PH, Maclure M, et al. Analysis of possible triggers of acute myocardial infarction (the MILIS study). Am J Cardiol. 1990;66:22–27
  12. Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res. 1999;41:402–417
  13. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT. Inflammatory and non invasive vascular markers: the multi marker approach for risk stratification in coronary artery disease. Atherosclerosis. 2008 Feb 29;[Epub ahead of print]
  14. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–671
  15. Molloy K, Loftus IM. Mechanisms of plaque rupture. In:  Fitridge R,  Thompson M editor. Mechanisms of vascular disease. Cambridge University Press; 2007;p. 103–126
  16. Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking induced dysfunction of nitric oxide biosynthesis and up regulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation. 2003;107:2342–2347
  17. Kolodgie FD, Burke AP, Farb A, Gold HK, Yuan J, Narula J, et al. The thin-cap fibroatheroma: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol. 2001;16:285–292
  18. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol. 2007;27:15–26
  19. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) investigators. Circulation. 1998;98:839–844
  20. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  21. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  22. Alvarez Garcia B, Ruiz C, Chacon P, Sabin JA, Matas M. High sensitivity CRP in high grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg. 2003;38:1018–1024
  23. Di Napoli M, Papa F, Bocola V. CRP in ischaemic stroke. Stroke. 2001;32:917
  24. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of CRP and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462–466
  25. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of CRP and risk of developing peripheral vascular disease. Circulation. 1998;97:425–428
  26. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  27. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high risk individuals: a randomised placebo controlled trial. Lancet. 2002;360:7–22
  28. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of CRP for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–1965
  29. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103:1191–1193
  30. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1998;95:8880–8885
  31. Shovman O, Levy Y, Gilburd B, Shoenfeld Y. Anti-inflammatory and immunomodulatory properties of statins. Immunol Res. 2002;25:271–285
  32. Selzman CH. Mechanistic approaches to therapy for vascular injury. In:  Clark LV editors. Trends in atherosclerosis research. Nova Science Publications; 2004;p. 1–34
  33. Selzman CH, Shames BD, Miller SA, Pulido EJ, Meng X, Mcintyre RC, et al. Therapeutic implications of IL-10 in surgical disease. Shock. 1998;10:309–318
  34. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. J Am Med Assoc. 1998;279:1643–1650
  35. Galis ZS, Asanuma K, Godin D, Meng X. N-Acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy. Circulation. 1998;97:2445–2453
  36. Ferns GA, Forster L, Stewart-Lee A, et al. Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc Natl Acad Sci USA. 1992;89:11312–11316
  37. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450–1456
  38. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444–1449
  39. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781–786
  40. Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infraction. Lancet. 1997;349:1715–1720
  41. Levonen AL, Vahakangas E, Koponen JK, Yla-Herttuala S. Antioxidant gene therapy for cardiovascular disease: current status and future perspectives. Circulation. 2008;117:2142–2150
  42. Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, et al. Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297:1675–1682
  43. Brewer HB. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Curr Cardiol Rep. 2007;9:486–492
  44. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042–1050
  45. Lin CP, Chen YH, Lin WT, Leu HB, Liu TZ, Huang SL, et al. Direct effect of statins on homocysteine-induced endothelial adhesiveness: potential impact to human atherosclerosis. Eur J Clin Invest. 2008;38:106–116
  46. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, et al. Infection with Chlamydia pneumoniae accelerates the development of atheroscerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97:633–636
  47. Ossei-Gerning N, Moayyedi P, Smith S, Braunholtz D, Wilson JI, Axon AT, et al. Helicobacter pylori infection is related to atheroma in patients undergoing coronary angiography. Cardiovasc Res. 1997;35:120–124
  48. Nieto FJ, Adam E, Sorlie P, Farzadegan H, Melnick JL, Comstock GW, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of sub clinical atherosclerosis. Circulation. 1996;94:922–927
  49. Kaukoranta-Tolvanen SS, Ronni T, Leinonen M, Saikku P, Laitinen K. Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microb Pathog. 1996;21:407–411
  50. Heinemann M, Susa M, Simnacher U, Marre R, Essig A. Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in a human monocytic cell line. Infect Immun. 1996;64:4872–4875
  51. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression. Circulation. 1998;98:300–307
  52. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation. 2002;106:1219–1223
  53. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Investigators in the WIZARD Study Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA. 2003;290:1459–1466
  54. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995;92:1565–1569
  55. Loftus IM, Naylor AR, Bell PRF, Thompson MM. MMPs and atherosclerotic plaque instability. Br J Surg. 2002;89:680–694
  56. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863–868
  57. Mauviel A. Cytokine regulation of metalloproteinase gene expression. J Cell Biochem. 1993;53:288–295
  58. Gogly B, Hornebeck W, Groult N, Godeau G, Pellat B. Influence of heparin(s) on the interleukin-1β-induced expression of collagenase, stromelysin-1, and tissue inhibitor of metalloproteinase-1 in human gingival fibroblasts. Biochem Pharmacol. 1998;56:1447–1454
  59. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost. 2001;86:324–333
  60. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111–122
  61. Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, Bell PRF, et al. A prospective randomised double blinded trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke. 2002;33:2858–2864
  62. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW, Kent KC, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicentre study. J Vasc Surg. 2002;36:1–12
  63. Jander S, Sitzer M, Wendt A, Schroeter M, Buchkremer M, Siebler M, et al. Expression of tissue factor in high-grade carotid artery stenosis: association with plaque destabilization. Stroke. 2001;32:850–854
  64. Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis and vascular remodelling. Circ Res. 2001;89:1–2
  65. Moreno PR, Bernardi VH, López-Cuéllar J, Murcia AM, Palacios IF, Gold HK, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation. 1996;94:3090–3097
  66. Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2008;28:233–242
  67. Steins MB, Padró T, Li CX, Mesters RM, Ostermann H, Hammel D, et al. Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis. 1999;145:173–180
  68. Padró T, Steins M, Li CX, Mesters RM, Hammel D, Scheld HH, et al. Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants. Cardiovasc Res. 1997;36:28–36

PII: S1078-5884(08)00283-9

doi: 10.1016/j.ejvs.2008.06.002

European Journal of Vascular & Endovascular Surgery
Volume 36, Issue 5 , Pages 507-516 , November 2008

Article Tools

* Image Usage & Resolution